Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study.  PLoS Medicine.  16. 2019
2019 Stereotactic radiosurgery with MLC-defined arcs: Verification of dosimetry, spatial accuracy, and end-to-end tests.  Journal of Applied Clinical Medical Physics.  20:84-98. 2019
2019 Pathologic Predictors of Local Recurrence in Atypical Meningiomas Following Gross Total Resection.  International Journal of Radiation Oncology - Biology - Physics.  103:453-459. 2019
2019 Differential escape mechanisms in cetuximab-resistant head and neck cancer cells.  Biochemical and Biophysical Research Communications.  2019
2018 The virtual cone: A novel technique to generate spherical dose distributions using a multileaf collimator and standardized control-point sequence for small target radiation surgery.  Advances in Radiation Oncology.  3:421-430. 2018
2018 MicroRNA-31 is required for astrocyte specification.  Glia.  66:987-998. 2018
2018 A method for pre-operative single-subject thalamic segmentation based on probabilistic tractography for essential tremor deep brain stimulation.  Neuroradiology.  60:303-309. 2018
2018 Postoperative radiosurgery for the treatment of metastatic brain tumor: Evaluation of local failure and leptomeningeal disease.  Journal of Clinical Neuroscience.  49:48-55. 2018
2018 Structural connectivity–based segmentation of the thalamus and prediction of tremor improvement following thalamic deep brain stimulation of the ventral intermediate nucleus.  NeuroImage: Clinical.  20:1266-1273. 2018
2017 Macropinocytosis of bevacizumab by glioblastoma cells in the perivascular niche affects their survival.  Clinical Cancer Research.  23:7059-7071. 2017
2017 Fractionated stereotactic radiation therapy for intact brain metastases.  Advances in Radiation Oncology.  2:564-571. 2017
2017 Epigenetic regulation of ZBTB18 promotes glioblastoma progression.  Cell Growth and Differentiation.  15:998-1011. 2017
2017 KLF6 depletion promotes NF-κB signaling in glioblastoma.  Oncogene.  36:3562-3575. 2017
2017 Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era a correlative analysis based on nrg oncology RTOG 0525.  JAMA Oncology.  3:784-792. 2017
2017 Distant brain recurrence in patients with five or more newly diagnosed brain metastases treated with focal stereotactic radiotherapy alone..  Journal of Radiosurgery and SBRT.  4:255-263. 2017
2016 Coneless Linear Accelerator-Based Volumetric Modulated Arc Therapy Stereotactic Radiosurgery Technique for Functional Disorders..  International Journal of Radiation Oncology - Biology - Physics.  96:E657-E658. 2016
2016 Distant Brain Recurrence in Patients With 5 or More Newly Diagnosed Brain Metastases Treated With Stereotactic Radiosurgery (SRS) or Fractionated Stereotactic Radiation Therapy (FSRT) Alone..  International Journal of Radiation Oncology - Biology - Physics.  96:E67. 2016
2016 Stereotactic Hypofractionated Radiation Therapy for Intact Brain Metastases..  International Journal of Radiation Oncology - Biology - Physics.  96:E120-E121. 2016
2016 A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas.  Journal of Neuro-Oncology.  129:139-146. 2016
2016 SU-F-J-96: Comparison of Frame-Based and Mutual Information Registration Techniques for CT and MR Image Sets..  Medical Physics.  43:3428-3429. 2016
2015 Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition.  BMC Cancer.  15. 2015
2015 Neuronal activity promotes glioma growth through neuroligin-3 secretion.  Cell.  161:803-816. 2015
2015 Connexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapy.  Neuro-Oncology.  17:392-406. 2015
2015 Loss of tumor suppressive microRNA-31 enhances TRADD/NF-κB signaling in glioblastoma.  Oncotarget.  6:17805-17816. 2015
2014 Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: The University of Alabama at Birmingham experience.  Neuro Oncology Practice.  1:172-177. 2014
2014 Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression.  Journal of Clinical Investigation.  124:2861-2876. 2014
2014 A20 expressing tumors and anticancer drug resistance.  Advances in Experimental Medicine and Biology.  809:65-81. 2014
2014 Illuminating radiogenomic characteristics of glioblastoma multiforme through integration of MR imaging, messenger RNA expression, and DNA copy number variation.  Radiology.  270:212-222. 2014
2014 Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.  Radiotherapy and Oncology.  111:468-474. 2014
2013 Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.  Clinical Cancer Research.  19:6484-6494. 2013
2013 Feature selection and survival modeling in The Cancer Genome Atlas.  International Journal of Nanomedicine.  8:57-62. 2013
2013 RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.  International Journal of Radiation Oncology - Biology - Physics.  85:1206-1211. 2013
2012 Laminin alpha 2 enables glioblastoma stem cell growth.  Annals of Neurology.  72:766-778. 2012
2012 Glioblastoma multiforme.  Neurology Research International.  2012. 2012
2012 Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma.  Journal of Cellular and Molecular Medicine.  16:545-554. 2012
2011 Gene-protein correlation in single cells.  Neuro-Oncology.  13:880-885. 2011
2011 The authors reply.  New England Journal of Medicine.  365:277-278. 2011
2011 Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.  Cell.  146:53-66. 2011
2011 Nonreceptor Tyrosine Kinase BMX Maintains Self-Renewal and Tumorigenic Potential of Glioblastoma Stem Cells by Activating STAT3.  Cancer Cell.  19:498-511. 2011
2011 NFKBIA deletion in glioblastomas.  New England Journal of Medicine.  364:627-637. 2011
2010 A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.  Cancer.  116:5297-5305. 2010
2009 Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.  BMC Cancer.  9:372. 2009
2009 Translating biological insights into clinical endpoints in neuro-oncology.  Lancet Oncology.  10:928-929. 2009
2009 A network model of a cooperative genetic landscape in brain tumors.  Journal of the American Medical Association.  302:261-275. 2009
2009 Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas.  Journal of the American Medical Association.  302:276-289. 2009
2009 Role of IκBα as a negative regulator of EGFR and a molecular determinant of prognosis in glioblastoma multiforme..  Journal of Clinical Oncology.  27:2028. 2009
2009 Genomics of human intracranial aneurysm wall.  Stroke.  40:1252-1261. 2009
2008 Use of gene signatures to improve risk estimation in cancer.  Journal of the American Medical Association.  299:1605-1606. 2008
2008 Nomograms as clinicobiological predictors of survival in glioblastoma.  Lancet Oncology.  9:5-6. 2008
2007 Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors.  Methods in Molecular Biology.  377:187-202. 2007
2007 CHD5 Is a Tumor Suppressor at Human 1p36.  Cell.  128:459-475. 2007
2007 Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors..  Methods in Molecular Biology.  377:187-202. 2007
2006 Tumor necrosis factor-α-induced protein 3 down-regulates nuclear factor-κB-mediated drug resistance in vitro and is a favorable clinical prognostic factor in human glioblastomas..  Journal of Clinical Oncology.  24:1508. 2006
2006 Tumor necrosis factor-α-induced protein 3 as a putative regulator of nuclear factor-κB-mediated resistance to O6-alkylating agents in human glioblastomas.  Journal of Clinical Oncology.  24:274-287. 2006
2005 Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas.  Cancer Research.  65:8679-8689. 2005
2005 893 High-resolution Mapping of Human Glioma Genomes..  Neurosurgery.  57:427-428. 2005
2005 High-resolution genome-wide mapping of genetic alterations in human glial brain tumors.  Cancer Research.  65:4088-4096. 2005
2005 Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA.  Journal of Molecular Diagnostics.  7:171-182. 2005
2005 DNA topoisomerase IIalpha and Her-2/neu gene dosages in pediatric malignant gliomas..  International Journal of Oncology.  26:1187-1192. 2005
2004 Chemogenomics: An emerging strategy for rapid target and drug discovery.  Nature Reviews Genetics.  5:262-275. 2004
2004 Genomics-based hypothesis generation: A novel approach to unravelling drug resistance in brain tumours?.  Lancet Oncology.  5:89-100. 2004
2003 Predicting outcome and tailoring treatment in high-grade gliomas.  Lancet Oncology.  4:269-270. 2003
2003 Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: Evidence for distinct angiogenic subtypes.  Brain Pathology.  13:133-143. 2003
2002 Expression of DNA topoisomerase IIα in oligodendroglioma.  Anticancer Research.  22:1301-1304. 2002
2002 High expression of DNA topoisomerase IIα and Ki-67 antigen is associated with prolonged survival in glioblastoma patients.  European journal of cancer.  38:1343-1347. 2002
2002 DNA topoisomerase IIα predicts progression-free and overall survival in pediatric malignant non-brainstem gliomas.  International Journal of Cancer.  99:817-820. 2002
2002 Expression of DNA topoisomerase IIalpha in oligodendroglioma..  Anticancer Research.  22:1301-1304. 2002
2002 DNA topoisomerase IIα expression in optic pathway gliomas of childhood.  European journal of cancer.  38:393-400. 2002
2002 Brain-tumour drug resistance: The bare essentials.  Lancet Oncology.  3:397-406. 2002
2001 Anticancer drug resistance in primary human brain tumors.  Brain Research Reviews.  35:161-204. 2001
1999 Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II - Preclinical studies in a nude mouse model.  Neurosurgery.  45:1208-1215. 1999
1999 Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.  Clinical Cancer Research.  5:1786-1792. 1999
1999 Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion.  Journal of Neuro-Oncology.  41:9-20. 1999
1999 The p21-Ras signal transduction pathway and growth regulation in human high-grade gliomas.  Brain Research Reviews.  29:232-249. 1999
1998 Application of signal transduction inhibition as a therapeutic strategy for central nervous system tumors.  Pediatric Neurosurgery.  29:228-244. 1998
1998 Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth.  Neurosurgery.  43:124-132. 1998
1997 Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas.  Clinical Cancer Research.  3:2157-2164. 1997
1997 The role of protein kinase C (PKC) in the evolution and proliferation of malignant gliomas, and the application of PKC inhibition as a novel approach to anti-glioma therapy.  Acta Neurochirurgica.  139:1000-1013. 1997

Chapter

Year Title Altmetric
2014 Primary Tumors of the Nervous System 2014
2013 Primary Tumors of the Nervous System.  1-22. 2013

Principal Investigator On

Investigator On

Education And Training

  • Doctor of Medicine, University of Vienna 2001
  • Doctor of Philosophy in Medical Neurobiology, Free University of Berlin 2001
  • UAB Hospital, Residency 2014
  • Stanford University School of Medicine, Postdoctoral Fellowship 2005

    • Full Name

  • Markus Bredel